Nitazoxanide

Nitazoxanide
	File:Nitazoxanide.svg
Clinical data
Pregnancy; category	US: B (No risk in non-human studies) ; ;
Routes of; administration	Oral (tablets and suspension)
ATC code	P01AX11 (WHO) ;
Legal status
Legal status	US: ℞-only ;
Pharmacokinetic data
Protein binding	99%
Metabolism	Hydrolyzed to tizoxanide
Excretion	Renal, biliary and fecal
Identifiers
	IUPAC name [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate;
CAS Number	55981-09-4;
PubChem CID	41684;
DrugBank	APRD00558;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C12H9N3O5S
Molar mass	307.283 g/mol

Nitazoxanide, also known by the brand names Alinia and Annita, is a synthetic nitrothiazolyl-salicylamide derivative and an antiprotozoal agent. It is approved for the treatment of infectious diarrhea caused by Cryptosporidium parvum and Giardia lamblia in patients 1 year of age and older.

Nitazoxanide is currently in Phase II clinical trials for the treatment of hepatitis C, in combination with peginterferon alfa-2a and ribavirin.^[1]^[2]

Adverse effects

Side effects are mostly gastrointestinal, and include abdominal pain, vomiting and diarrhea.

Pharmacokinetics

Nitazoxanide is a prodrug. Following oral administration, it is rapidly hydrolyzed to its active metabolite, tizoxanide, which is 99% protein bound. Peak concentrations are observed 1–4 hours after administration. It is excreted in the urine, bile and feces.

References

Notes

↑ "Romark Initiates Clinical Trial Of Alinia® For Chronic Hepatitis C In The United States" (Press release). Medical News Today. August 16 2007. Retrieved 2007-10-11. Check date values in: |date= (help)
↑ Franciscus, Alan (October 2 2007). "Hepatitis C Treatments in Current Clinical Development". HCV Advocate. Retrieved 2007-10-11. Check date values in: |date= (help)

Sources

Mosby's Drug Consult 16th Edition (2006)
"Nitazoxanide". MedlinePlus Drug Information. U.S. National Library of Medicine. January 1 2006. Retrieved 2007-10-11. Check date values in: |date= (help)
Romark Pharmaceuticals. Alinia® (nitazoxanide) tablets and for oral suspension prescribing information. Tampa, FL: 2005 Jun.
"Parasitic infections". Am J Transplant. 4 Suppl 10: 142–55. 2004. doi:10.1111/j.1600-6135.2004.00677.x. PMID 15504227.

Template:Agents against amoebiasis and other protozoal diseases Template:WikiDoc Sources

[1] "Romark Initiates Clinical Trial Of Alinia® For Chronic Hepatitis C In The United States" (Press release). Medical News Today. August 16 2007. Retrieved 2007-10-11. Check date values in: |date= (help)

[2] Franciscus, Alan (October 2 2007). "Hepatitis C Treatments in Current Clinical Development". HCV Advocate. Retrieved 2007-10-11. Check date values in: |date= (help)

[1]

[2]